Background Patients with impaired liver function (ILF) were excluded from clinical trials that
investigated non–vitamin K antagonist oral anticoagulants (NOAC s) for stroke prevention in …

Background The effect of non-vitamin K antagonist oral anticoagulants (NOACs) in patients
with atrial fibrillation (AF) and liver disease remains largely unresolved. Therefore, we …

Background Liver cirrhotic patients with nonvalvular atrial fibrillation have been excluded
from randomized clinical studies regarding oral anticoagulants for stroke prevention …

Background Patients with atrial fibrillation (AF) have a higher risk of developing
thromboembolic events. Current guidelines recommend the use of oral anticoagulants for …

Background: Non–vitamin K antagonist oral anticoagulants (NOACs) are relatively new
drugs used for stroke prevention in nonvalvular atrial fibrillation (NVAF). However, there are …

Background Major randomized trials assessing non–vitamin K antagonist oral
anticoagulants (NOAC s) for stroke prevention in atrial fibrillation generally excluded …

Aims Anticoagulation for atrial fibrillation patients with liver disease represents a clinical
dilemma. We sought to evaluate the efficacy/safety of different anticoagulation, ie vitamin K …

Background Liver disease is associated with increased bleeding risk. The efficacy and
safety of direct oral anticoagulants (DOACs) is a subject of contention in atrial fibrillation (AF) …

Background: Advanced liver disease is known to increase the risk for bleeding and affects
the hepatic clearance and metabolism of drugs. Subjects with active liver disease were …

Background and Purpose: Limited data support the benefits of non–vitamin K oral
anticoagulants (NOACs) among atrial fibrillation patients with prior gastrointestinal bleeding …